Project Grant HT94252510454
Award Date
9/1/25
Completion Date
8/31/27
Dollars Obligated
$616K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Mobile, AL 36608, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $525,799 to the University of Alabama for a 3-year period from September 1, 2025 to August 31, 2028. The funding supports research aimed at "TARGETING GPNMB TO IMPROVE EFFICACY OF CDK4/6 INHIBITORS IN ER+ BREAST CANCER". The University of Alabama, through its Office for Sponsored Programs Division, will conduct advanced biomedical research...
This federal Project Grant award of $1,622,612.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports preclinical validation of novel combination therapeutic strategies targeting KRAS and BRAF mutated colorectal cancer. The award was granted to The University of Texas M.D. Anderson Cancer Center to conduct this advanced biomedical research, with the goal of enabling near-term clinical examination of the developed therapies. The 3-year project...
The University of Alabama at Birmingham (UAB) was awarded a $733,662 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, supports research to investigate the role of tumor glycans in immune suppression. This federally funded project aims to advance scientific understanding of how specific carbohydrate molecules on tumor cells can inhibit the body's immune response, with the goal of...
This Project Grant award of $1,177,716.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of Alabama at Birmingham (UAB) to investigate the "Metabolic Regulation of Metastatic Potential Through mRNA Translation." The award, which began on July 15, 2024 and will run through July 14, 2028, aims to advance scientific understanding of cancer metastasis through the study of metabolic processes and...
This Project Grant award of $1,113,750.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), supports the University of Alabama at Birmingham (UAB) in developing "DUAL CD24/CD276 TARGETING THERAPIES FOR TRIPLE-NEGATIVE BREAST CANCER." The 3-year award, running from August 1, 2023 to July 31, 2026, will fund research to investigate medical solutions for the battlefield and transform health care for service members and the public...
This Project Grant award of $650,845, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research at the University of Alabama at Birmingham (UAB) focused on developing macrophage-centric prognostic biomarkers for checkpoint blockade immunotherapy in melanoma. The research aims to transform healthcare for military service members, veterans, and the broader public by investigating innovative medical...
The University of Alabama at Birmingham was awarded a $220,326 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on April 1, 2025, with a completion date of March 31, 2027, supports the development of novel, selective PARP protein degraders for prostate cancer treatment, utilizing PSMA uptake enhancement. This research aims to transform healthcare for military service members, veterans, and the broader...
The Defense Health Agency awarded a $321,404 Project Grant to the University of Birmingham under the Military Medical Research and Development program (CFDA 12.420) to support "The Application of AI-Defined Molecular Classifications in Ovarian Cancer". The award, which commenced on September 1, 2024 and runs through August 31, 2026, will enable the University of Birmingham to conduct innovative biomedical research aimed at improving health outcomes for military service members,...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...